GlassScriptPhysician profile
Adrian E Carreon
NPI 1679598536
$4,079.36
in general payments reported to CMS, 2019-2025
28 companies · $355 in 2025
The $355 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $834 · 2020: $303 · 2021: $576 · 2022: $480 · 2023: $515 · 2024: $1,018 · 2025: $355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,887.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,887.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $689.06 | 2019-2025 | Ozempic |
| Amgen INC. | $598.19 | 2019-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $578.53 | 2022-2025 | Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $459.20 | 2021-2025 | Airsupra, Breztri |
| Lilly USA, LLC | $317.80 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Abbvie INC. | $205.73 | 2021-2024 | |
| Amarin Pharma, INC. | $193.45 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $135.00 | 2023 | Ingrezza |
| Novartis Pharmaceuticals Corporation | $122.83 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $80.59 | 2019-2021 | |
| Astellas Pharma US INC | $71.26 | 2019-2023 | Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.91 | 2019-2022 | |
| Esperion Therapeutics, INC. | $63.55 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $54.04 | 2019-2021 | |
| Baxter Healthcare | $52.44 | 2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Monarch Airway Clearance System |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $52.19 | 2021 | |
| Merck Sharp & Dohme LLC | $50.05 | 2022-2024 | Gardasil, Gardasil 9, Capvaxive |
| Pfizer INC. | $49.60 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $49.60 | 2022-2024 | |
| Philips North America LLC | $37.40 | 2022-2025 | Vest Therapy Und |
| Allergan, INC. | $25.20 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $25.13 | 2022 | |
| Mylan Specialty L.P. | $24.21 | 2022 | |
| Mimedx Group, INC. | $18.11 | 2024 | |
| Hologic Sales and Service, LLC | $17.42 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.70 | 2022 | |
| Almatica Pharma LLC | $13.37 | 2022 | |
| Tactile Systems Technology INC | $10.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrian Carreon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.